DNLI (Denali Therapeutics) Stock Based Compensation: $95.09 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNLI Denali Therapeutics Inc DNLI
33 GF Score
Price $25.69
! 6 Warning Signs
View Full Analysis

What is Denali Therapeutics Stock Based Compensation?

Denali Therapeutics DNLI +5.63% 33 Stock Based Compensation is $95.09 Mil as of Jun. 2026. GuruFocus rates DNLI with a GF Score™ of 33/100. The stock has 6 warning signs investors should review.

Denali Therapeutics's Stock Based Compensation for the three months ended in Jun. 2026 was $22.92 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was $95.09 Mil.

Denali Therapeutics Stock Based Compensation Related Terms

Denali Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Denali Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics Stock Based Compensation Chart

Denali Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.25 99.85 108.10 102.88 99.63

Denali Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.39 25.14 23.95 23.09 22.92
DNLI
33GF Score
Denali Therapeutics Inc DNLI
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Denali Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $95.09 Mil.

What does a Stock Based Compensation of $95.09 Mil mean?
Denali Therapeutics (DNLI) has a Stock Based Compensation of $95.09 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Denali Therapeutics and its competitors.
Is Denali Therapeutics' Stock Based Compensation too high?
Denali Therapeutics' current Stock Based Compensation is $95.09 Mil. Overall, Denali Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Stock Based Compensation compare to RCUS and ALMS?
Denali Therapeutics' Stock Based Compensation of $95.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Denali Therapeutics and its competitors. Denali Therapeutics's current Stock Based Compensation is $95.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (DNLI) has a current Stock Based Compensation of $95.09 Mil. The current Stock Based Compensation is $95.09 Mil. Denali Therapeutics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Denali Therapeutics (DNLI), the current Stock Based Compensation is $95.09 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Denali Therapeutics Business Description

Other Exchanges 4DN:GermanyD2NL34:Brazil
Address 161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
33GF Score

Get the complete analysis for DNLI

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.69
Price